Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

September 23, 2021

Study Completion Date

July 7, 2022

Conditions

Small Cell Lung Cancer (SCLC)

Interventions

DRUG

Nab-paclitaxel

Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle

Trial Locations (1)

University of Iowa Hospitals and Clinics, Iowa City